Gilead Sciences Wins FDA Approval For Biktarvy

Gilead Sciences looks like a good oversold, candle over candle setup.

Gilead Sciences received approval from the FDA for Biktarvy, a once-daily combination of three drugs (bictegravir /emtricitabine/tenofovir alafenamide or BIC/FTC/TAF) for the treatment of HIV-1 infection. The company stands to reap up to a potential $5 billion in sales revenue from the approval.
Continue reading “Gilead Sciences Wins FDA Approval For Biktarvy”

Is Ionis Pharmaceuticals Stock Ready To Explode Higher?

The chart of Ionis Pharmaceuticals doesn’t look like much but the fundamentals show eye-popping revenue growth.

Will 2018 be the year that Ionis Pharmaceuticals' stock explodes higher?

Synergy Pharmaceuticals Ahead of PDUFA

Synergy Pharmaceuticals has a PDUFA ruling coming within the next couple of days. The Twiggs Money Flow has started to run ahead of the FDA announcement.

Synergy Pharmaceuticals stock is starting to run higher ahead of its PDUFA date. Find out if you should be playing this stock for a quick pop.

Amgen Stock Setup On FDA Approval for Multiple Myeloma

Amgen stock looks like a good setup as the Twiggs Money Flow breaks into positive territory.


  • The FDA has approved Amgen's supplemental Biologics License Application to expand the label of its key drug Xgeva.
  • Amgen stock is in a continuation pattern and the Twiggs Money Flow has just gone positive.
  • Amgen has nearly $39 billion in cash overseas that could be put to use in the United States.
  • Sofi AI Market Sentiment Gauge

    Sofi AI Market Sentiment Gauge

    Market is extremely oversold. Good time to take long positions.